This medication is used to treat plaque psoriasis and certain types of arthritis (such as arthritis of the spine, psoriatic arthritis, axial spondyloarthritis, enthesitis-related arthritis). Secukinumab belongs to a class of drugs known as monoclonal antibodies.

Cosentyx contains secukinumab. This is a type of drug called a biologic, which is made from a living or natural source. Cosentyx is a kind of biologic called a monoclonal antibody. Monoclonal antibodies are proteins that work to decrease inflammation.

In clinical trials, the majority of people taking COSENTYX 300 mg were clear or almost clear at 12 weeks. Approximately 8 out of 10 people saw 75% skin clearance, and approximately 6 out of 10 people saw 90% skin clearance. In clinical trials, many people who saw results at 1 year maintained them at 5 years.

The biologic drug Cosentyx (secukinumab) can weaken your immune system, increasing your risk of infection. Two of the most common adverse reactions to the drug were colds and upper respiratory tract infections in clinical trials, but this occurred in less than 1% of people.

The most common side effects of COSENTYX include cold symptoms, diarrhea, and upper respiratory infections. COSENTYX may cause serious allergic reactions. Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking COSENTYX.

The COSENTYX prefilled syringes may be stored at room temperature, up to 86°F (30°C), for up to 4 days. provided on the carton. Throw away the COSENTYX prefilled syringe if it has been kept outside of the refrigerator over 4 days.

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have died from these infections. Your doctor should check you for tuberculosis (TB) before starting treatment with COSENTYX.

Results fast. Clear skin that can last. In clinical trials, the majority of people taking COSENTYX 300 mg were clear or almost clear at 12 weeks. Approximately 8 out of 10 people saw 75% skin clearance. Approximately 6 out of 10 people saw 90% skin clearance. Many who saw results at 1 year maintained them at 5 years.

Proven results can last. For adults who continued on COSENTYX for 5 years, a similar percentage saw an improvement in PsA symptoms. At 1 year, adults and doctors knew they were getting COSENTYX, which may affect results.

Real-World Data Suggest Long-Term Treatment With Secukinumab Is Safe, Effective. Findings are based on a retrospective, multicenter study carried out in Spain. New research details the long-term safety and efficacy of secukinumab in bio-naïve patients with moderate to severe cutaneous psoriasis.

Results fast. Clear skin that can last. In clinical trials, the majority of people taking COSENTYX 300 mg were clear or almost clear at 12 weeks. Approximately 8 out of 10 people saw 75% skin clearance. Approximately 6 out of 10 people saw 90% skin clearance. Many who saw results at 1 year maintained them at 5 years.